top of page

Using a covalent menin inhibitor as an approach against diabetes (and more) with Biomea Fusion's CEO

Thomas Butler describes Biomea's hypothesis of utilizing a covalent, irreversible menin inhibitor to promote beta cell proliferation in diabetes. He reviews Biomea's latest clinical data, and highlights the company's cancer programs.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page